STOCK TITAN

DuPont Completes Divestiture of Aramids Business

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

DuPont (NYSE:DD) completed the divestiture of its Aramids business (Kevlar and Nomex) to Arclin on April 1, 2026, in a transaction valuing the business at approximately $1.8 billion. DuPont receives ~$1.2 billion cash (pre-tax), a $300 million note receivable and a $325 million non-controlling equity stake, representing an approximate 16% ownership. The Aramids results were reclassified as discontinued operations beginning in third quarter 2025 for current and historical periods.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • Transaction value of approximately $1.8 billion
  • DuPont receives ~$1.2 billion in pre-tax cash proceeds
  • Receives a $300 million note receivable and $325 million equity stake
  • Retains an approximate 16% non-controlling interest in Arclin

Negative

  • Cash proceeds of $1.2 billion are materially below $1.8 billion valuation
  • Sale results reclassified as discontinued operations, reducing continuing operations base
  • Non-controlling stake means DuPont loses operational control of Aramids

News Market Reaction – DD

+0.90%
1 alert
+0.90% News Effect

On the day this news was published, DD gained 0.90%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Transaction value: $1.8 billion Cash proceeds: $1.2 billion Note receivable: $300 million +3 more
6 metrics
Transaction value $1.8 billion Valuation of Aramids business divestiture
Cash proceeds $1.2 billion Pre-tax cash proceeds from Aramids divestiture
Note receivable $300 million Note receivable received in divestiture
Equity interest value $325 million Current value of non-controlling equity interest in Arclin
Equity stake 16% Expected non-controlling common equity stake in Arclin
Reclassification timing Third quarter 2025 Aramids results reported as discontinued operations from this period

Market Reality Check

Price: $48.12 Vol: Volume 2,413,064 is below...
low vol
$48.12 Last Close
Volume Volume 2,413,064 is below the 20-day average of 4,452,780, suggesting the move preceded this headline or lacked heavy participation. low
Technical Shares at $45.78 are trading above the 200-day MA $37.64 and about $6.88 below the 52-week high of $52.66.

Peers on Argus

DD gained 3.57% while key peers were mixed: PPG +1.42%, IFF +1.51%, but APD -0.7...

DD gained 3.57% while key peers were mixed: PPG +1.42%, IFF +1.51%, but APD -0.75%, LYB -1.93%, RPM -0.02%, pointing to a stock-specific move.

Historical Context

5 past events · Latest: Mar 30 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Mar 30 Water project impact Positive -2.3% New Kenya water treatment plant expected to benefit up to 20,000 people.
Mar 26 Product upgrade launch Positive -0.7% Launch of upgraded nanofiltration element targeting lower energy use and costs.
Mar 18 Reverse split proposal Neutral -1.1% Plan to seek approval for reverse stock split between 1-for-2 and 1-for-4.
Mar 18 Reverse split correction Neutral -1.1% Clarifying correction on reverse split details and record date timing.
Mar 11 Innovation award Positive +0.0% Award for transformational innovation in industrial water reuse technologies.
Pattern Detected

Recent positive operational and recognition news often saw flat or negative next-day reactions, indicating a tendency for muted or contrarian price responses to favorable headlines.

Recent Company History

Over the past month, DuPont issued several operational and corporate updates. Water technology launches and innovation awards in March 2026 coincided with flat-to-negative moves, while announcements related to a proposed reverse stock split on March 18, 2026 also saw modest declines. The current aramids divestiture completion follows the March 16 8-K about its expected closing, extending a series of portfolio and capital-structure actions alongside ongoing product innovation.

Market Pulse Summary

This announcement finalizes DuPont’s Aramids divestiture, valuing the business at $1.8 billion and d...
Analysis

This announcement finalizes DuPont’s Aramids divestiture, valuing the business at $1.8 billion and delivering $1.2 billion in pre-tax cash, a $300 million note, and a minority equity stake currently valued at $325 million. Aramids results have been reported as discontinued operations since Q3 2025, so ongoing financials already excluded them. Investors may track how DuPont redeploys cash and how the retained 16% Arclin stake performs over time.

Key Terms

note receivable, non-controlling common equity interest, discontinued operations
3 terms
note receivable financial
"pre-tax cash proceeds of approximately $1.2 billion... a note receivable of $300 million"
A note receivable is a formal, written promise from a borrower to pay a lender a specific amount plus interest by a set date; the lender records it as an asset that represents expected future cash. For investors, it signals a company’s upcoming cash flow and credit exposure—like a timed IOU—so size, interest rate and the borrower’s reliability affect the company’s liquidity and risk profile.
non-controlling common equity interest financial
"a non-controlling common equity interest in Arclin currently valued at $325 million"
An ownership stake consisting of common shares that does not give the holder the power to control a company’s decisions or board. It matters to investors because these shares share in profits, losses and liquidation proceeds like any common stock but typically have limited influence over strategy and governance; think of it as owning a few seats at a large table — you share the meal and risk but can’t decide the menu, which affects value and liquidity.
discontinued operations financial
"results of the Aramids business were reclassified and reported as discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

AI-generated analysis. Not financial advice.

WILMINGTON, Del., April 1, 2026 /PRNewswire/ -- DuPont (NYSE:DD) today announced it has completed the previously-announced divestiture of its Aramids business (Kevlar® and Nomex®) to Arclin, a portfolio company of an affiliate of TJC, L.P. (TJC), in a transaction valuing the business at approximately $1.8 billion.

With the close of the transaction, DuPont receives pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in Arclin currently valued at $325 million, which is expected to represent an approximate 16% stake.

The results of the Aramids business were reclassified and reported as discontinued operations beginning in third quarter 2025 for current and historical periods.

About Arclin
Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products, and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design, and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities across North & South America, Europe, and Asia and serves customers worldwide. For more information, visit www.arclin.com.

About TJC
TJC, L.P., formerly known as The Jordan Company, has worked for more than 40 years with CEOs, founders and entrepreneurs across a range of industries including Consumer, Diversified Industrials, Healthcare, Industrial Technology, Logistics & Business Services and Digital & Power Infrastructure. With $30.9 billion of assets under management as of September 30, 2025, TJC is managed by a senior leadership team that has invested together for over 24 years on over 90 investments. TJC has offices in New York, Chicago, Miami and Stamford. For more information, please visit www.tjclp.com.

About DuPont
DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target, "outlook," "stabilization," "confident," "preliminary," "initial," and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements, including statements regarding outlook, expectations and guidance.  Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dupont-completes-divestiture-of-aramids-business-302731294.html

SOURCE DuPont

FAQ

What did DuPont (DD) announce about the Aramids divestiture on April 1, 2026?

DuPont completed the sale of its Aramids business to Arclin for about $1.8 billion. According to the company, DuPont received roughly $1.2 billion cash (pre-tax), a $300 million note receivable, and a $325 million equity stake (~16%).

How much cash did DuPont (DD) receive from the Aramids sale on April 1, 2026?

DuPont received approximately $1.2 billion in pre-tax cash proceeds from the transaction. According to the company, this amount is subject to customary transaction adjustments alongside a $300 million note and a $325 million equity interest.

What is the value and ownership percentage of DuPont's remaining stake in Arclin after the DD Aramids sale?

DuPont holds a non-controlling common equity interest valued at about $325 million, representing roughly a 16% stake. According to the company, this equity position accompanies the cash and note receivable components of the transaction.

How will the Aramids transaction affect DuPont (DD) financial reporting periods?

Results for the Aramids business were reclassified as discontinued operations starting in third quarter 2025. According to the company, current and historical periods reflect this reclassification for comparability and reporting purposes.

What consideration did DuPont (DD) receive besides cash in the Aramids divestiture?

In addition to about $1.2 billion cash, DuPont received a $300 million note receivable and a $325 million equity stake in Arclin. According to the company, these components constitute the contractual consideration for the transaction.